MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared With Placebo in Adult Patients With Cervical Dystonia

    M. Lew, D. Snyder (Los Angeles, CA, USA)

    Objective: To determine the efficacy and safety of a 500 U/2 mL dilution of aboBoNT-A as compared to placebo in patients with cervical dystonia (CD).…
  • 2017 International Congress

    Rehabilitation program with or without a whey protein-based nutritional support enriched with essential aminoacids and vitamin D in patients with Parkinson’s disease or parkinsonism: study design of a randomized, controlled trial.

    m. barichella, E. Cereda, G. Pinelli, l. Iorio, V. Ferri, g. Frazzitta, E. Cassani, G. Riboldazzi, G. Pezzoli (Milano, Italy)

    Objective: Objective. To evaluate whether the use of a whey protein-based nutritional formula enriched with essential aminoacids – particularly leucine - and vitamin D have…
  • 2017 International Congress

    A randomised control trial to investigate if people with Parkinson’s disease can exercise at high intensity, and does this improve their cardiorespiratory function? A feasibility study

    M. Harvey, R. Walker, W. Gray, K. Weston, L. Oates (North Shields, United Kingdom)

    Objective: To assess whether people with Parkinson’s disease (PD) are able to exercise at ≥85% of maximal heart rate during High Intensity Interval Training (HIIT)…
  • 2017 International Congress

    Are the exergaming effective for improving functional exercise capacity, and quality of life in Patients with Parkinson’s Disease?

    C. Gemin, L. da Silva, M. Ribas Correa, H. Ghizone Teive, S. Valderramas (curitiba, Brazil)

    Objective: To analyze the effects of exergaming on functional exercise capacity and quality of life in patients with Parkinson's disease Background: The use of technology,…
  • 2017 International Congress

    A Phase 2, Open-Label, Dose-Escalating Study to Evaluate the Safety and Preliminary Efficacy of Daxibotulinumtoxina for Injection (RT002) in Isolated Cervical Dystonia

    C. Comella, J. Jankovic, D. Truong, A. Brashear, A. Patel, M. Evatt, C. Chung, R. Rubio (Chicago, IL, USA)

    Objective: To report preliminary 24-week outcomes of an open-label trial of daxibotulinumtoxinA for injection (RT002) for the treatment of isolated cervical dystonia (CD). (ClinicalTrials.gov ID: NCT02706795) Background:…
  • 2017 International Congress

    Motor and Body Composition Variables by Parkinson’s Disease Staging

    L. LEANDRO, C. MOREIRA, H. TEIVE (Curitiba, Brazil)

    Objective: Knowing the motor variables involved in the relationship of body composition and staging of disease. Background: Functional limitation, defined as a restriction in the…
  • 2017 International Congress

    Physical Mobility Predictors and the Bone Health in Parkinson’s Disease

    L. LEANDRO, C. MOREIRA, H. TEIVE (Curitiba, Brazil)

    Objective: Evaluate the physical mobility and functionality by the ratio of bone mineral density in Parkinson’s disease. Background: Bone loss in Parkinson’s disease (PD) may…
  • 2017 International Congress

    Postural control is maintained after a 8-months period of exercise in people with Parkinson’s disease

    L. Gobbi, N. Rinaldi, P. Pelicioni, E. Lirani-Silva, L. Moraes, M. Pereira (Rio Claro, Brazil)

    Objective: Our aim was to investigate the effects of different long-lasting exercises programs on the postural control in people with Parkinson’s disease (PD). Background: Postural…
  • 2017 International Congress

    WTX101 – A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study

    D. Bega, A. Ala, F. Askari, J. Bronstein, A. Czlonkowska, P. Ferenci, D. Nicholl, K.-H. Weiss, M. Schilsky (Chicago, IL, USA)

    Objective: The objective of this study was to evaluate the efficacy and safety of 24 week WTX101 treatment in newly diagnosed Wilson Disease (WD) patients. Background:…
  • 2017 International Congress

    A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome

    D. Gilbert, T. Murphy, J. Jankovic, C. Budman, K. Black, R. Kurlan, K. Coffman, J. McCracken, J. Juncos, J. Grant, R. Chipkin (Cincinnati, OH, USA)

    Objective: To investigate the efficacy and safety of the selective dopamine D1 receptor antagonist ecopipam in children and adolescents with Tourette Syndrome (TS). Background: Dysregulation…
  • « Previous Page
  • 1
  • …
  • 1694
  • 1695
  • 1696
  • 1697
  • 1698
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley